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SObjective: A follow-up integrated positron emission tomography/computed tomography (PET/CT), as part of
a more intensive surveillance program, has been performed at around 1 year after curative resection, regardless
of the patients’ symptoms or findings in other tests. This study was designed to evaluate the results of this follow-
up integrated PET/CT in patients treated for non–small-cell lung cancer without symptoms or abnormal findings.
Methods: Between January 2003 and December 2006, this study enrolled 86 patients with non–small cell lung
cancer who had no clinical or radiologic evidence of recurrence after curative resection before integrated PET/CT
and underwent a follow-up integrated PET/CT around 1 year at our institution.
Results: The time from operation to the follow-up integrated PET/CT check was 13.4  4.4 months. Integrated
PET/CT showed negative findings in 41 (47.7%) patients, equivocal findings in 16 (18.6%) patients, and positive
findings in 29 (33.7%) patients. Twenty-seven (31.4%) patients had recurrent disease and 2 patients had extra-
thoracic double primary cancer. Six patients had extrathoracic recurrence without intrathoracic recurrence.
Conclusions: A postoperative follow-up integrated PET/CT can be used for early detection of recurrence in
asymptomatic patients who had had resection of non–small-cell lung cancer. Further studies are required to eval-
uate the cost-effectiveness or survival benefit of follow-up integrated PET/CT. (J Thorac Cardiovasc Surg
2010;139:1447-51)Surgery is the most appropriate treatment for early-stage
non–small-cell lung cancer (NSCLC). Although 5-year sur-
vivals of more than 60% can be achieved in selected patients,
overall, more than 50% of those undergoing resection will
die of a recurrence.1 The majority of recurrences are distant,
and more than 80% occur within the first 2 years.2 Many cli-
nicians have tried to detect early signs of second primary lung
cancer or recurrence at a treatable stage through postopera-
tive surveillance to increase survival. However, there is no
consensus on the best follow-up program after curative resec-
tion for NSCLC. Retrospective studies endorsed the concept
of less intensive surveillance (symptom-based) because more
intensive surveillance has not yet demonstrated benefit in
survival and quality of life.3-6 In contrast, recent studies
have demonstrated that asymptomatic recurrences detected
by intensive surveillance had a better prognosis than symp-
tomatic recurrence.2,7 As a result, recent guidelines from
the National Comprehensive Cancer Network (NCCN) and
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The Journal of Thoracic and Carchest computed tomography (CT) every 6 months for 2 years
for surveillance imaging.8,9
Although a chest CT can detect changes consistent with
recurrence earlier than a chest radiograph, unfortunately
the performance characteristics of the chest CT result in dif-
ficulty in distinguishing nonspecific posttreatment changes
related to surgery from a recurrence or metachronous double
primary lung cancer. In contrast, positron emission tomogra-
phy (PET) and CT, using 18F-fluorodeoxyglucose (inte-
grated FDG–PET/CT) as a metabolic imaging tool, may
be able to distinguish recurrence from scarring, pleural
thickening, and mediastinal fibrosis commonly found after
surgical resection.10 In addition, integrated PET/CT can bet-
ter assess the status of disease and stratify prognosis than
conventional staging and might also affect patient manage-
ment.11,12 Therefore, a follow-up integrated PET/CT, as
part of a more intensive surveillance program, has been per-
formed at around 1 year after curative resection in patients
without symptoms or abnormal findings in other tests.
This study was designed to evaluate the results of this fol-
low-up integrated PET/CT in patients who had NSCLC
without symptoms or abnormal findings.PATIENTS AND METHODS
Patients
This study is a retrospective review of a prospective lung cancer data-
base. We enrolled patients with NSCLC who had no clinical or radiologic
evidence of recurrence after curative resection before integrated PET/CT
and underwent a follow-up integrated PET/CT around 1 year at our institu-
tion. All patients underwent complete anatomic resection and mediastinaldiovascular Surgery c Volume 139, Number 6 1447
TABLE 1. Patient characteristics
No. %
Age (y, mean, range) 61.2 35–76
Sex, male 64 74.4
Histologic type
Squamous 49 57.0
Adenocarcinoma 31 36.0
Bronchioloalveolar 4 4.7
Others 2 2.3
Pathologic stage
IA 20 23.3
IB 36 41.9
IIA 3 3.5
IIB 12 13.9
IIIA 15 17.4
Adjuvant therapy
Chemotherapy 8 9.3
Radiotherapy 9 10.5
Chemoradiotherapy 2 2.3
Abbreviations and Acronyms
ACCP ¼ American College of Chest Physicians
CT ¼ computed tomography
FDG ¼ 18F-fluorodeoxyglucose
MRI ¼ magnetic resonance imaging
NCCN ¼ National Comprehensive Cancer
Network
NSCLC ¼ non–small-cell lung cancer
PET ¼ positron emission tomography
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Snode dissection. Patients were excluded if they had integrated PET/CT
when recurrence was suspected on the basis of symptoms or results of other
tests or if they refused PET/CT. Informed consent was obtained from eligi-
ble patients after we provided detailed explanations about cost, necessity,
and expected effects of integrated PET/CT. This study was approved by
the Institutional Review Board of Kyunpook National University Hospital.
Integrated PET/CT Acquisition and Processing
FDG–PET scans were obtained on a Hi-Rez Reveal PET/CT scanner
(CTI Molecular Imaging, Inc, Knoxville, Tenn), which combined a lutetium
oxyorthosilicate crystal PET scanner with a 6-slice CT scanner. After fast-
ing for at least 6 hours, patients received an intravenous injection of 370
MBq (10 mCi) of 18F-FDG and were instructed to rest in a quiet room
with dimmed lights.
Interpretation of Integrated PET/CT
PET/CT findings were classified as negative if imaging showed no focal
FDG uptake suggestive of recurrence. Findings that could not be clearly
characterized and that would require follow-up were defined as equivocal.
Focal FDG uptake with an intensity higher than that of surrounding tissues
was defined as positive.
Postoperative Surveillance
Follow-ups were conducted every 3 months for 2 years. These included
history-taking, chest radiograph, physical examination, and tumor marker
(carcinoembryonic antigen, neuron-specific enolase, and/or Cyfra 21-1 but
only if elevated before the operation). In addition, a chest CT was taken every
6 months. If a recurrence was suspected, either through newly presenting
symptoms or scheduled tests, then integrated PET/CT was performed. If pa-
tients showed no symptoms or abnormal findings in the scheduled test, inte-
grated PET/CT was performed approximately 1 year after curative resection.
Recurrences
In principle, final diagnosis of recurrence was confirmed by histopatho-
logic examination of samples obtained from surgery or biopsy. If it was im-
possible to diagnose the recurrence histopathologically, exclusion of
recurrent malignancy was based on a clinical and radiologic follow-up pe-
riod of at least 12 months with no evidence of active malignancy. If brain
metastases were suspected in integrated PET/CT, immediate brain magnetic
resonance imaging (MRI) was performed in all patients.
RESULTS
Patient Background
Eighty-six patients (64 men, 22 women; mean age, 61.2
years) who had no clinical or radiologic evidence of recur-
rence underwent a follow-up integrated PET/CT to evaluate
recurrence around 1 year after curative resection (Table 1).1448 The Journal of Thoracic and Cardiovascular SurThe pathologic staging of the tumors, determined according
to the guidelines of the American Joint Cancer Committee,
was as follows: 20 patients had stage IA, 36 patients had stage
IB, 3 patients had stage IIA, 12 patients had stage IIB, and 15
patients had stage IIIA. The histologic type of the lung can-
cers, determined according to the World Health Organization
classifications, was as follows: 49 (57.0%) cases were squa-
mous cell carcinomas, 31 (36.0%) were adenocarcinomas,
and 4 (4.7%) were bronchioloalveolar carcinomas. All pa-
tients in the study underwent potentially curative surgery
consisting of a lobectomy (n ¼ 83) or a pneumonectomy (n
¼ 3) with complete mediastinal lymph node dissection.
Twelve patients had neoadjuvant therapy before curative re-
section. Adjuvant chemotherapy, radiation therapy, or che-
moradiotherapy was performed in 8 (9.3%) patients, 9
(10.5%) patients, and 2 (2.3%) patients, respectively.Results of Integrated PET/CT
The time from operation to the follow-up integrated PET/
CT check was 13.4  4.4 months. Results of the integrated
PET/CT showed negative findings in 41 (47.7%) patients,
equivocal findings in 16 (18.6%) patients, and positive find-
ings in 29 (33.7%) patients (Figure 1).Recurrence
Of 86 patients, 27 (31.4%) patients had recurrent disease
with a mean follow-up duration of 31.3 12.8 months and 2
(2.3%) patients had extrathoracic double primary cancer
(Table 2). Recurrence was diagnosed by histologic examina-
tion in 9 (33.3%) patients and by serial imaging in 18
(66.7%) patients. The most commonly involved organ
was the contralateral lung and lymph node in 9 (33.3%) pa-
tients, followed by the ipsilateral lung and lymph node in 7
(25.9%) patients, the liver in 5 (18.5%) patients, the bone ingery c June 2010
FIGURE 1. One patient had definite evidence of recurrence, which showed newly developed high and focal hypermetabolic lesions. A, A preoperative in-
tegrated PET/CT showed no hypermetabolic lesions except for the primary mass. B, A follow-up integrated PET/CT after curative resection showed hyper-
metabolism at the right interlobar nodes and left scapula, but there were no symptoms related to these lesions. C, Left scapular lesion was confirmed as
metastasis of lung cancer by shoulder MRI.
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S4 (14.8%) patients, the brain in 3 (11.1%) patients, and the
adrenal gland in 2 (7.4%) patients. According to pathologic
stage, 9 (33.3%) patients in stage I, 10 (37.1%) patients in
stage II, and 8 (29.6%) patients in stage IIIA had a recur-
rence. Of 16 patients who had a recurrence in lung paren-
chyma, 9 patients underwent invasive biopsy for
histopathologic examination and showed the same histo-
logic type as was present before the first operation. Six
(22.2%) patients had only extrathoracic distant metastasisTABLE 2. Recurrence characteristics
No. %
No. of recurrences (% of total patients) 27 31.4
Follow-up duration (mean  SD) 31.3  12.8
Methods by diagnosis
Histologic examination 9 33.3
Serial follow-up 18 66.7
Locations
Contralateral lung and lympe node 9 33.3
Ipsilateral lung and lymph node 7 25.9
Liver 5 18.5
Bone 4 14.8
Brain 3 11.1
Adrenal 2 7.4
According to pathologic stage
I 9 33.3
II 10 37.1
III 8 29.6
The Journal of Thoracic and Carwithout intrathoracic recurrence (Figure 2). Extrathoracic
double primary cancer was detected in 2 patients; one was
bladder cancer and the other was colon cancer. Both patients
underwent surgical resection in the departments of urology
and general surgery, respectively.
Postrecurrence Therapy
Surgery was performed on 4 patients for the initial recur-
rence. Chest wall resection with wedge resection was per-
formed on 2 patients, only wedge resection on 1 patient,
and adrenalectomy on 1 patient. However, 23 patients re-
ceived nonsurgical therapy: 12 were treated with chemother-
apy, 4 with radiotherapy, and 5 with chemoradiation therapy;
the remaining 2 patients received supportive care only.
Survival
Of 27 patients with recurrence, 15 (55.6%) died of dis-
ease progression and 12 (44.4%) are still alive with or with-
out recurrence. One patient who underwent adrenalectomy
at 14 months after the first operation was still alive at 37
months with no evidence of recurrent disease. Two patients
who had extrathoracic double primary cancer are still alive
without recurrent lung cancer.
DISCUSSION
This study showed that integrated PET/CT detected occult
metastases in 27 of 86 patients with no symptoms or nodiovascular Surgery c Volume 139, Number 6 1449
FIGURE 2. An asymptomatic patient manifested extrathoracic recurrence without intrathoracic recurrence. A, A follow-up integrated PET/CT after curative
resection showed hypermetabolism at the thoracic spine. B, MRI of the spine confirmed bone metastasis of lung cancer.
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Sabnormal findings in scheduled tests after curative resection
of NSCLC. As a result, integrated PET/CT might be useful
as a follow-up tool even in cases in which recurrence is not
suspected after curative resection. A number of previous
studies have shown the usefulness of integrated PET/CT
for suspected recurrent NSCLC after curative resection.11-13
In those studies, the sensitivity, specificity, and accuracy
values of integrated PET/CT for diagnosis of recurrence
was around 90%. As a single-time modality, therefore, inte-
grated PET/CT can confirm suspected recurrence and be
used to assess the status of disease.12 However, no studies
have been conducted regarding the use of the integrated
PET/CT to detect recurrence when it is not suspected after
curative resection. To the best of our knowledge, the present
study is the first to address integrated PET/CT in this type of
clinical setting. How often and by what means surveillance
should be carried out is debatable, mainly owing to the
lack of evidence that earlier treatment of recurrence leads
to a better outcome.14 The American Society of Clinical On-
cology guidelines for NSCLC state that there is no proven
value for either chest radiograph or CT in surveillance and
recommend only history-taking and physical examination
every 3 months.15 However, there is considerable interest
in developing noninvasive, easily performed, safe, and accu-
rate techniques for detecting recurrences or metachronous
double primary lung cancer at the earliest possible time.
Guidelines from the American College of Radiology, in ad-
dition to NCCN and ACCP guidelines, recommend a postre-
section chest CT at 3 months to establish a new baseline and
then an annual check-up.16 However, it is still uncertain
whether early detection of cancer recurrence in asymptom-1450 The Journal of Thoracic and Cardiovascular Suratic patients positively affects prognosis. Virgo and associ-
ates3 demonstrated no differences in survival time in an
intensive surveillance group, and Younes, Gross, and De-
heinzelin6 also found that intensive surveillance yielded no
survival advantage and was more expensive than a symp-
tom-based surveillance. Although the asymptomatic patients
had a longer survival time after detection of recurrence,
Walsh and colleagues4 believed that this reflected lead-
time bias and not a true survival benefit. In contrast, Westeel,
Choma, and Clement7 found good compliance with an inten-
sive surveillance regimen in a subset of the entire group, and
survival after recurrence for patients with asymptomatic re-
currences was significantly better than for patients with
symptomatic recurrences. Sugimura and coworkers2 showed
treatment for recurrent NSCLC significantly prolonged sur-
vival and concluded that surgery should be considered. They
also investigated independent prognostic factors of postre-
currence survival and demonstrated that the presence of
symptoms was a poor prognostic factor.2 In our institution,
an intensive surveillance program has been adopted after cu-
rative resection for NSCLC. It consists of regular visits, tu-
mor marker evaluation every 3 months, and a chest CT every
6 months. When patients report specific symptoms at their
regular visit, various types of diagnostics (eg, brain MRI,
bone scan, and abdominal and pelvic CT) are performed to
rule out recurrence. These procedures are time-consuming
and costly if 2 or more diagnostics are needed. Therefore,
a simpler and more efficient diagnostic tool to help deter-
mine systemic status safely and reliably is needed. For this
reason, we performed a follow-up integrated PET/CT after
curative resection in patients having NSCLC. We foundgery c June 2010
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Sthe advantages of integrated PET/CT to be early detection of
recurrence in the absence of symptoms or abnormal findings
and extrathoracic recurrence in the absence of intrathoracic
recurrence. When an asymptomatic patient has distant me-
tastases accompanied by intrathoracic recurrence, distant
metastases can be detected through other types of examina-
tion. However, when a patient with asymptomatic recur-
rence has extrathoracic metastasis only, early diagnosis is
impossible because the routine test is focused only on the
thorax. In this study, integrated PET/CT detected extrathora-
cic recurrence in a total of 6 patients with no intrathoracic re-
currence. As for brain metastasis, the usefulness of a PET
might be decreased because physiologic accumulation of
FDG occurs in the brain. However, understanding of PET/
CT findings and whole-body PET/CT would be helpful in
evaluating brain metastasis.17 Brain metastases in 3 patients
who were asymptomatic were detected by integrated whole-
body PET/CT, which was confirmed by brain MRI. Inte-
grated PET/CT can also detect the extrathoracic double pri-
mary cancer, as shown by our results.
Our study has a number of limitations. First, there was no
control group receiving an intensive surveillance with
a method other than integrated PET/CT. Our study, how-
ever, was not intended to compare integrated PET/CT with
chest CT. Because there are no data of integrated PET/CT
in a surveillance program, our study provides new informa-
tion about the early detection of cancer recurrence in asymp-
tomatic patients with NSCLC. Second, we did not evaluate
the extent to which early detection of recurrence through in-
tegrated PET/CT influenced the prognosis (an assessment of
survival gain). Inasmuch as this study involved a small num-
ber of patients and the follow-up observation period was rel-
atively short, further studies are necessary to address this.
Third, although patients with abnormal findings on inte-
grated PET/CT were found to have recurrence on 12-month
follow-up imaging, not all the recurrences were confirmed
through histologic examination. Fourth, differentiating a sec-
ond double primary lung cancer from recurrence is difficult.
We determined our cases to be recurrence rather than second
double primary lung cancer because the recurrences were
found within 2 years and with mediastinal node metastasis.The Journal of Thoracic and CarCONCLUSIONS
Integrated PET/CT can be a useful diagnostic tool to de-
tect cancer recurrence in NSCLC patients without symptoms
or abnormal findings. Further studies are required to evalu-
ate the cost-effectiveness or survival benefit of follow-up in-
tegrated PET/CT.
References
1. Clifton F, Mountain MD. Revisions in the international system for staging lung
cancer. Chest. 1997;111:1711-7.
2. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps CD, et al.
Survival after recurrent non small-cell lung cancer after complete pulmonary
resection. Ann Thorac Surg. 2007;83:409-18.
3. Virgo KS, McKirgan LW, Caputo MCA, Mahurin DM, Chao LC, Caputo NA,
et al. Post-treatment management option for patients with lung cancer. Ann
Surg. 1995;222:700-10.
4. Walsh GL, O’Connor M, Willias KM, Milas M, Wong RS, Nesbitt JC, et al. Is
follow-up of lung cancer patients after resection medically indicated and cost-
effective? Ann Thorac Surg. 1995;60:1563-72.
5. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative
cancer therapy. A critical review and economic analysis. J Gen Intern Med. 1997;
12:318-31.
6. Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer. How often and
for what purpose? Chest. 1999;115:1494-9.
7. Westeel V, Choma D, Clement F. Relevance of an intensive postoperative follow-
up after surgery for non–small lung cancer. Ann Thorac Surg. 2000;70:1185-90.
8. Rubins J, Unger M, Colicce GL. Follow-up and surveillance of the lung cancer
patient following curative intent therapy: ACCP evidence-based clinical practice
guideline (2nd edition). Chest. 2007;132:355-67.
9. National Comprehensive Cancer Network. Practice guidelines for non–small cell
lung cancer. Rockledge (PA): National Comprehensive Cancer Network; 2000.
10. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging. 2006;
21:123-36.
11. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al.
The utility of F-FDG PET for suspected recurrent non–small cell lung cancer after
potentially curative therapy: impact on management and prognostic stratification.
J Nucl Med. 2001;42:1605-13.
12. Keidar Z, Haim N, Guranlnik L, Wollner M, Bar-Shalom R, Ben-Nun A, et al.
PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value
and impact on patient management. J Nucl Med. 2004;45:1640-6.
13. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, et al. Detecting
recurrent or residual lung cancer with FDG–PET. J Nucl Med. 1995;36:788-93.
14. Benamore R, Shepherd FA, Leighl N, Pintilie M, Patel M, Feld R, et al. Does
intensive follow-up alter outcome in patients with advanced lung cancer?
J Thorac Oncol. 2007;2:273-81.
15. American Society of Clinical Oncology treatment of unresectable non–small cell
lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-53.
16. Follow-up of non–small cell lung cancer: American College of Radiology appro-
priateness criteria, 2005.
17. Lee HY, Chung JK, Jeong JM, Lee DS, Kim DG, Jung HW, et al. Comparison of
FDG–PET findings of brain metastasis from non–small cell lung cancer and small-
cell lung cancer. Ann Nucl Med. 2008;22:281-6.diovascular Surgery c Volume 139, Number 6 1451
